Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Induction of Acute T-Cell Mediated Rejection in Hand Allotransplant by COVID-19 Infection.
Microsurgery
January 2025
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Liver kinase B1 (LKB1) staves off γδ T-cell-mediated autoimmune liver disease.
Cell Mol Immunol
June 2024
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence from a case of TNFAIP3 deficiency.
J Gastroenterol Hepatol
August 2024
Department of Gastroenterology and Hepatology, Bronglais General Hospital, Aberystwyth, UK.
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
Blood Cancer J
April 2024
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!